6533b829fe1ef96bd1289a68
RESEARCH PRODUCT
TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Marvin C. GershengornMonica C. SkarulisSusanne NeumannBrent S. AbelGeorge J. KahalyBernice Marcus-samuelsRobert F. PlaceChristine C KriegerCarmine Bevilacquasubject
0301 basic medicinemedicine.medical_specialtyLinsitinibEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismContext (language use)BiochemistryThyrotropin receptorReceptor IGF Type 1Graves' ophthalmopathyPathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineCyclic AMPMedicineHumansHyaluronic AcidReceptorCells Culturedbusiness.industryBiochemistry (medical)AutoantibodyReceptors ThyrotropinReceptor Cross-TalkOriginal Articlesmedicine.diseaseGraves Ophthalmopathy030104 developmental biologyEndocrinologychemistryMonoclonalbusinessOrbitdescription
AbstractContext:The TSH receptor (TSHR) is considered the main target of stimulatory autoantibodies in the pathogenesis of Graves' ophthalmopathy (GO); however, it has been suggested that stimulatory IGF-1 receptor (IGF-1R) autoantibodies also play a role.Objective:We previously demonstrated that a monoclonal stimulatory TSHR antibody, M22, activates TSHR/IGF-1R cross talk in orbital fibroblasts/preadipocytes obtained from patients with GO (GO fibroblasts [GOFs]). We show that cross talk between TSHR and IGF-1R, not direct IGF-1R activation, is involved in the mediation of GO pathogenesis stimulated by Graves' autoantibodies.Design/Setting/Participants:Immunoglobulins were purified from the sera of 57 GO patients (GO-Igs) and tested for their ability to activate TSHR and/or IGF-1R directly and TSHR/IGF-1R cross talk in primary cultures of GOFs. Cells were treated with M22 or GO-Igs with or without IGF-1R inhibitory antibodies or linsitinib, an IGF-1R kinase inhibitor.Main Outcome Measures:Hyaluronan (hyaluronic acid [HA]) secretion was measured as a major biological response for GOF stimulation. IGF-1R autophosphorylation was used as a measure of direct IGF-1R activation. TSHR activation was determined through cAMP production.Results:A total of 42 out of 57 GO-Ig samples stimulated HA secretion. None of the GO-Ig samples exhibited evidence for IGF-1R autophosphorylation. Both anti-IGF-1R antibodies completely inhibited IGF-1 stimulation of HA secretion. By contrast, only 1 IGF-1R antibody partially blocked HA secretion stimulated by M22 or GO-Igs in a manner similar to linsitinib, whereas the other IGF-1R antibody had no effect on M22 or GO-Ig stimulation. These findings show that the IGF-1R is involved in GO-Igs stimulation of HA secretion without direct activation of IGF-1R.Conclusions:IGF-1R activation by GO-Igs occurs via TSHR/IGF-1R cross talk rather than direct binding to IGF-1R, and this cross talk is important in the pathogenesis of GO.
year | journal | country | edition | language |
---|---|---|---|---|
2016-06-01 | The Journal of clinical endocrinology and metabolism |